| Pre-8/97 | Ancient Article | How the Elephants Dance Part 1 |
| | |
|
| Pre-8/97 | Ancient Article | How the Elephants Dance Part 2 |
| | |
|
| 06/23/10 | Buzz | Recap Roundup: 1Q 2010 |
| | |
|
| 11/14/08 | Turn Signal | Royalty Rates Revealed |
| | |
|
| 03/14/08 | Buzz | Starter Drugs: Aggrastat |
| | | Drug candidates get passed from one company to another for lots of reasons – including for use as a temporary stepping-stone to aid a young firm in its quest to become a major player in the biotech arena. We call these products starter drugs, and in this article we’ve focused on the development history of the cardiovascular drug Aggrastat.
|
| 11/14/07 | Buzz | Starter Drugs |
| | |
|
| 07/20/07 | Focal Point | Mega-Deals Not So Rare Anymore |
| | |
|
| 04/10/07 | Turn Signal | Alliance Trends: Deal Values Soar |
| | |
|
| 02/15/06 | Buzz | Partnering Deals: Watch Those Milestones |
| | |
|
| 02/17/05 | Buzz | Deal-Making Heads Upstream |
| | |
|
| 10/27/04 | Focal Point | Late-Stage Deals Have Lots of Appeal |
| | |
|
| 09/14/04 | Article | The Ties That (Don’t) Bind |
| | | Innovation, creativity, a collegial environment – these are all keys to Roche’s laissez faire approach to its biotech partnerships. Respecting autonomy and remaining flexible worked with Genentech, and it’s still working today.
|
| 02/12/04 | Focal Point | Partners Bid Up Mid-Stage Deals |
| | |
|
| 02/06/03 | Buzz | How The Elephants Dance Part 4 |
| | |
|
| 11/04/99 | Turn Signal | How The Elephants Dance Part 3 |
| | |
|